Back to News
Market Impact: 0.32
Sofwave Receives NMPA Approval in Mainland China
Source: GlobeNewswire
Healthcare & BiotechProduct LaunchesRegulation & Legislation
China's NMPA approved the product following a 200-subject randomized controlled trial that showed statistically significant improvement in mid-to-lower facial wrinkles. The study also reported a favorable safety profile, supporting commercialization potential in the Chinese aesthetics market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Trump, Xi Address AI, Taiwan During State Visit
- SEBI Allows Portfolio Managers to Invest Overseas, Short Equity Options
- Exclusive-How firms linked to sanctioned Chinese cotton giant sell clothes to U.S
- U.S. government seeks to join Elon Musk in challenge against EU's fine on X
- Tesla poised to scale production of heavy-duty Semi trucks with opening of Nevada factory
- Here’s the Tesla Semi… again